Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 04 Nov, 14:19 UTC

The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA). The post Kamau…